1
|
Ayesha, Ashraf A, Arshad M, Sajid N, Rasool N, Abbas M, Nazeer U, Khalid M, Imran M. Dinuclear Zn-Catalytic System as Brønsted Base and Lewis Acid for Enantioselectivity in Same Chiral Environment. ACS OMEGA 2024; 9:6074-6092. [PMID: 38375498 PMCID: PMC10876046 DOI: 10.1021/acsomega.3c07446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/26/2023] [Revised: 12/24/2023] [Accepted: 12/27/2023] [Indexed: 02/21/2024]
Abstract
Zinc (Zn) is a crucial element with remarkable significance in organic transformations. The profusion of harmless zinc salts in the Earth's outer layer qualifies zinc as a noteworthy contender for inexpensive and eco-friendly reagents and catalysts. Recently, widely recognized uses of organo-Zn compounds in the field of organic synthesis have undergone extensive expansion toward asymmetric transformations. The ProPhenol ligand, a member of the chiral nitrogenous-crown family, exhibits the spontaneous formation of a dual-metal complex when reacted with alkyl metal (R-M) reagents, e.g., ZnEt2. The afforded Zn complex possesses two active sites, one Lewis acid and the other Brønsted base, thereby facilitating the activation of nucleophiles and electrophiles simultaneously within the same chiral pocket. In this comprehensive analysis, we provide a thorough account of the advancement and synthetic potential of these diverse catalysts in organic synthesis, while emphasizing the reactivity and selectivities, i.e., dr and ee due to the design/structure of the ligands employed.
Collapse
Affiliation(s)
- Ayesha
- Department
of Chemistry, Government College University
Faisalabad, Faisalabad 38000, Pakistan
| | - Aisha Ashraf
- Department
of Chemistry, Government College University
Faisalabad, Faisalabad 38000, Pakistan
| | - Mahwish Arshad
- Department
of Chemistry, Government College University
Faisalabad, Faisalabad 38000, Pakistan
- Roy
and Diana Vagelos Laboratories, Department of Chemistry, University of Pennsylvania, 231 South 34th Street, Philadelphia, Pennsylvania 19104-6323, United States
| | - Numan Sajid
- Department
of Chemistry, Government College University
Faisalabad, Faisalabad 38000, Pakistan
| | - Nasir Rasool
- Department
of Chemistry, Government College University
Faisalabad, Faisalabad 38000, Pakistan
| | - Mujahad Abbas
- Department
of Chemistry, Government College University
Faisalabad, Faisalabad 38000, Pakistan
| | - Usman Nazeer
- Chemistry
Department, University of Houston, 3585 Cullen Boulvard, Houston, Texas 77204-5003, United States
| | | | - Muhammad Imran
- Chemistry
Department, Faculty of Science, King Khalid
University, P.O. Box 9004, Abha 61413, Saudi Arabia
| |
Collapse
|
2
|
Wu LH, Liu X, Liu ZW, Chen ZX, Fu XL, Yang K. Metal-free synthesis of difluoro/trifluoromethyl carbinol-containing chromones via tandem cyclization of o-hydroxyaryl enaminones. Org Biomol Chem 2023; 21:9236-9241. [PMID: 37966029 DOI: 10.1039/d3ob01582c] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2023]
Abstract
We herein propose a HFIP-promoted tandem cyclization reaction for the synthesis of difluoro/trifluoromethyl carbinol-containing chromones from o-hydroxyphenyl enaminones at room temperature. This protocol provides a facile and efficient approach to access diverse difluoro/trifluoromethylated carbinols in good to excellent yields. In addition, gram-scale and synthetic derivatization experiments have also been performed.
Collapse
Affiliation(s)
- Long-Hui Wu
- College of pharmacy, Gannan Medical University, Ganzhou 341000, P. R. China.
| | - Xia Liu
- College of pharmacy, Gannan Medical University, Ganzhou 341000, P. R. China.
| | - Zhao-Wen Liu
- College of pharmacy, Gannan Medical University, Ganzhou 341000, P. R. China.
| | - Zhi-Xi Chen
- College of pharmacy, Gannan Medical University, Ganzhou 341000, P. R. China.
| | - Xin-Lei Fu
- College of pharmacy, Gannan Medical University, Ganzhou 341000, P. R. China.
| | - Kai Yang
- College of pharmacy, Gannan Medical University, Ganzhou 341000, P. R. China.
| |
Collapse
|
3
|
Zhou B, Yang G, Wang C, Liu L, Shi L, Pan Z, Ji X, Wu L, Zheng H, Xu C, Fan L. Highly Chemoselective Synthesis of Azaarene-Equipped CF 3-Tertiary Alcohols under Metal-Free Conditions and Their Fungicidal Activities. ACS OMEGA 2022; 7:38084-38093. [PMID: 36312435 PMCID: PMC9609063 DOI: 10.1021/acsomega.2c05855] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/09/2022] [Accepted: 09/29/2022] [Indexed: 05/16/2023]
Abstract
A highly chemoselective reaction between α,β-unsaturated trifluoromethyl ketones with azaarenes under metal-free conditions was carried out, affording a range of valuable azaarene-equipped CF3-tertiary alcohols in moderate to excellent yields (up to 95% yield) with good tolerance of functional groups, and their structures were confirmed by NMR, HRMS, and X-ray diffraction for validation. This method features simple reaction conditions (only solvent), high atom- and step-economy, and broad substrate scope. Moreover, most of the target products exhibited promising fungicidal activities, and compound 3al exhibited 91.65% fungicidal activity against R. solani, with an EC50 value of 0.18 mg/mL.
Collapse
Affiliation(s)
- Bingyi Zhou
- College
of Sciences, Henan Agricultural University, Zhengzhou 450002, China
- College
of Tobacco Sciences, Henan Agricultural
University, Zhengzhou 450002, China
| | - Guoyu Yang
- College
of Sciences, Henan Agricultural University, Zhengzhou 450002, China
| | - Caixia Wang
- College
of Sciences, Henan Agricultural University, Zhengzhou 450002, China
| | - Lijie Liu
- College
of Sciences, Henan Agricultural University, Zhengzhou 450002, China
| | - Lijun Shi
- College
of Sciences, Henan Agricultural University, Zhengzhou 450002, China
| | - Zhenliang Pan
- College
of Sciences, Henan Agricultural University, Zhengzhou 450002, China
| | - Xiaoming Ji
- College
of Tobacco Sciences, Henan Agricultural
University, Zhengzhou 450002, China
| | - Lulu Wu
- College
of Sciences, Henan Agricultural University, Zhengzhou 450002, China
| | - Huayu Zheng
- College
of Sciences, Chang’an University, Xi’an 710064, China
| | - Cuilian Xu
- College
of Sciences, Henan Agricultural University, Zhengzhou 450002, China
| | - Liangxin Fan
- College
of Sciences, Henan Agricultural University, Zhengzhou 450002, China
| |
Collapse
|
4
|
Harcken C, Scholl P, Nabozny G, Thomson D, Bianchi D. Clinical profile of the functionally selective glucocorticoid receptor agonist BI 653048 in healthy male subjects. Expert Opin Investig Drugs 2019; 28:489-496. [PMID: 30908082 DOI: 10.1080/13543784.2019.1599859] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
BACKGROUND An efficacious anti-inflammatory corticosteroid with reduced side effects has been long sought. We report the pooled results from three clinical proof-of-mechanism Phase I studies of BI 653048 in healthy subjects, a functionally selective, nonsteroidal glucocorticoid (GC). RESEARCH DESIGN AND METHODS Three Phase I trials were conducted: a single rising-dose study and a multiple rising-dose study to evaluate the safety, tolerability, and pharmacokinetics of BI 653048, and a multiple parallel-arm-dose study with intravenous lipopolysaccharide challenge to assess in vivo pharmacodynamics. The pharmacodynamics, efficacy, and safety of BI 653048 and prednisolone were compared. RESULTS Treatment with 200 mg BI 653048 was associated with a reduced expression of IL1R2, ITGB3, and SDPR versus 20 mg prednisolone; comparable levels of FKBP5, ZBTB16, and DDIT4 expression were observed. Changes in C-peptide, glucose, insulin, and cortisol were moderate compared with prednisolone. A greater reduction of osteocalcin was observed with 200 mg BI 653048 versus 20 mg prednisolone. Comparable anti-inflammatory efficacy was demonstrated for 200 mg BI 653048 and 20 mg prednisolone. BI 653048 was well tolerated in healthy subjects. CONCLUSION BI 653048 demonstrated the desired anti-inflammatory effects of the nonsteroidal GC; however, the undesirable side-effect profile associated with GC steroids could not be disassociated from BI 653048. TRIAL REGISTRATION ClinicalTrials.gov identifiers NCT02217644, NCT02217631, and NCT02224105.
Collapse
Affiliation(s)
- Christian Harcken
- a Boehringer Ingelheim Pharmaceuticals, Inc ., Ridgefield , CT , USA
| | - Paul Scholl
- a Boehringer Ingelheim Pharmaceuticals, Inc ., Ridgefield , CT , USA
| | - Gerald Nabozny
- a Boehringer Ingelheim Pharmaceuticals, Inc ., Ridgefield , CT , USA
| | - David Thomson
- a Boehringer Ingelheim Pharmaceuticals, Inc ., Ridgefield , CT , USA
| | - Daniel Bianchi
- a Boehringer Ingelheim Pharmaceuticals, Inc ., Ridgefield , CT , USA
| |
Collapse
|
5
|
Immadi SS, Dopart R, Wu Z, Fu B, Kendall DA, Lu D. Exploring 6-Azaindole and 7-Azaindole Rings for Developing Cannabinoid Receptor 1 Allosteric Modulators. Cannabis Cannabinoid Res 2018; 3:252-258. [PMID: 30547095 PMCID: PMC6290480 DOI: 10.1089/can.2018.0046] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
Introduction and Objective: Org27569 is a prototypical allosteric modulator of the cannabinoid receptor 1 (CB1). It belongs to the indole-2-carboxamide scaffold and has been intensively investigated in pharmacology and in structure-activity relationship (SAR) studies. Although azaindoles are rare in natural products and differ only by the presence of an extra ring nitrogen, they were demonstrated as valuable bioisosteres in many pharmacologically important molecules. To extend the SAR investigation of the indole-2-carboxamide class of CB1 allosteric modulators, azaindole (pyrrolopyridine) rings were used to replace the indole ring of Org27569 analogs to explore the potential of azaindole-2-carboxamides as CB1 allosteric modulators. Using 6- and 7-azaindole in lieu of the indole moiety within this class of CB1 allosteric modulators indeed improved the aqueous solubility. Materials and Methods: We synthesized 6- and 7-azaindole-2-carboxamides and their indole-2-carboxamide counterparts. The molecules were evaluated by [3H]CP55,940 binding and [35S]GTPγS binding assays for their allosteric modulation of the CB1 receptor. Results: The 7-azaindole-2-carboxamides lost the ability to bind to the CB1 receptor. The 6-azaindole-2-carboxamides (e.g., 3c and 3d) showed markedly reduced binding affinities to the CB1 receptor in comparison with their indole-2-carboxamide counterparts. However, they behaved similarly as indole-2-carboxamides in potentiating the orthosteric agonist binding and inhibiting the orthosteric agonist-induced G-protein coupling. The results indicated that some azaindole scaffolds (e.g., 6-azaindole) are worth further exploration, whereas the 7-azaindole ring is not a viable bioisostere of the indole ring in the Org27569 class of CB1 allosteric modulators.
Collapse
Affiliation(s)
- Sri Sujana Immadi
- Department of Pharmaceutical Sciences, Rangel College of Pharmacy, Health Science Center, Texas A&M University, Kingsville, Texas
| | - Rachel Dopart
- Department of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut
| | - Zhixing Wu
- Department of Pharmaceutical Sciences, Rangel College of Pharmacy, Health Science Center, Texas A&M University, Kingsville, Texas
| | - Boqiao Fu
- Department of Pharmaceutical Sciences, Rangel College of Pharmacy, Health Science Center, Texas A&M University, Kingsville, Texas
| | - Debra A. Kendall
- Department of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut
| | - Dai Lu
- Department of Pharmaceutical Sciences, Rangel College of Pharmacy, Health Science Center, Texas A&M University, Kingsville, Texas
| |
Collapse
|
6
|
Synthesis, spectroscopic analysis (FT-IR, UV and NMR) and DFT analysis of novel prodrugs of pregnane, their apoptotic activity in cervical cancer cell lines. J Mol Struct 2018. [DOI: 10.1016/j.molstruc.2018.04.009] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
7
|
Hua YZ, Chen JW, Yang H, Wang MC. Asymmetric Friedel–Crafts Alkylation of Indoles with Trifluoromethyl Pyruvate Catalyzed by a Dinuclear Zinc Catalyst. J Org Chem 2018; 83:1160-1166. [DOI: 10.1021/acs.joc.7b02599] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- Yuan-Zhao Hua
- College of Chemistry and Molecular
Engineering, School of Pharmaceutical Sciences, Zhengzhou University, No. 100, Science Road, Zhengzhou, Henan 450000, P. R. China
| | - Jun-Wei Chen
- College of Chemistry and Molecular
Engineering, School of Pharmaceutical Sciences, Zhengzhou University, No. 100, Science Road, Zhengzhou, Henan 450000, P. R. China
| | - Hua Yang
- College of Chemistry and Molecular
Engineering, School of Pharmaceutical Sciences, Zhengzhou University, No. 100, Science Road, Zhengzhou, Henan 450000, P. R. China
| | - Min-Can Wang
- College of Chemistry and Molecular
Engineering, School of Pharmaceutical Sciences, Zhengzhou University, No. 100, Science Road, Zhengzhou, Henan 450000, P. R. China
| |
Collapse
|
8
|
Safy M, de Hair MJH, Jacobs JWG, Buttgereit F, Kraan MC, van Laar JM. Efficacy and safety of selective glucocorticoid receptor modulators in comparison to glucocorticoids in arthritis, a systematic review. PLoS One 2017; 12:e0188810. [PMID: 29267302 PMCID: PMC5739390 DOI: 10.1371/journal.pone.0188810] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2017] [Accepted: 10/23/2017] [Indexed: 12/20/2022] Open
Abstract
Background Long-term treatment with glucocorticoids (GCs) plays an important role in the management of arthritis patients, although the efficacy/safety balance is unfavorable. Alternatives with less (severe) adverse effects but with good efficacy are needed. Selective GC receptor modulators (SGRMs) are designed to engage the GC receptor with dissociative characteristics: transactivation of genes, which is mainly responsible for unwanted effects, is less strong while trans-repression of genes, reducing inflammation, is maintained. It is expected that SGRMs thus have a better efficacy/safety balance than GCs. A systematic review providing an overview of the evidence in arthritis is lacking. Objective To systematically review the current literature on efficacy and safety of oral SGRMs in comparison to GCs in arthritis. Methods A search was performed in Medline, Embase and the Cochrane Library, from inception dates of databases until May 2017. Experimental studies involving animal arthritis models or human material of arthritis patients, as well as clinical studies in arthritis patients were included, provided they reported original data. All types of arthritis were included. Data was extracted on the SGRM studied and on the GC used as reference standard; the design or setting of the study was extracted as well as the efficacy and safety results. Results A total of 207 articles was retrieved of which 17 articles were eligible for our analysis. Two studies concerned randomized controlled trials (RCT), five studies were pre-clinical studies using human material, and 10 studies involved pre-clinical animal models (acute and/or chronic arthritis induced in mice or rats). PF-04171327, the only compound investigated in a clinical trial setting, had a better efficacy/safety balance compared to GCs: better clinical anti-inflammatory efficacy and similar safety. Conclusion Studies assessing both efficacy and safety of SGRMs are scarce. There is limited evidence for dissociation of anti-inflammatory and metabolic effects of the SGRMs studied. Development of many SGRMs is haltered in a preclinical phase. One SGRM showed a better clinical efficacy/safety balance.
Collapse
Affiliation(s)
- M Safy
- Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands
| | - M J H de Hair
- Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands
| | - J W G Jacobs
- Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands
| | - F Buttgereit
- Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - M C Kraan
- Department of Rheumatology and Inflammation Research at Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
| | - J M van Laar
- Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands
| |
Collapse
|
9
|
Jiang L, Hu B, Xie X, Zhang Z. Asymmetric carbonyl-ene reaction of trifluoropyruvate catalyzed by Pd(II)-SunPhos complex. Tetrahedron 2017. [DOI: 10.1016/j.tet.2017.10.044] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
10
|
Berger M, Rehwinkel H, Schmees N, Schäcke H, Edman K, Wissler L, Reichel A, Jaroch S. Discovery of new selective glucocorticoid receptor agonist leads. Bioorg Med Chem Lett 2017; 27:437-442. [DOI: 10.1016/j.bmcl.2016.12.047] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2016] [Revised: 12/15/2016] [Accepted: 12/18/2016] [Indexed: 10/20/2022]
|
11
|
Abraham Y, Gerrits B, Ludwig MG, Rebhan M, Gubser Keller C. Exploring Glucocorticoid Receptor Agonists Mechanism of Action Through Mass Cytometry and Radial Visualizations. CYTOMETRY PART B-CLINICAL CYTOMETRY 2017; 92:42-56. [DOI: 10.1002/cyto.b.21499] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/19/2016] [Revised: 11/18/2016] [Accepted: 12/01/2016] [Indexed: 01/09/2023]
Affiliation(s)
- Yann Abraham
- Developmental and Molecular Pathway, Computational Biology; Novartis Institute for Biomedical Research; Novartis Campus CH-4056 Basel, Switzerland
| | - Bertran Gerrits
- Developmental and Molecular Pathway, Computational Biology; Novartis Institute for Biomedical Research; Novartis Campus CH-4056 Basel, Switzerland
| | - Marie-Gabrielle Ludwig
- Developmental and Molecular Pathway Immunity; Novartis Institute for Biomedical Research; Novartis Campus CH-4056 Basel, Switzerland
| | - Michael Rebhan
- Developmental and Molecular Pathway, Computational Biology; Novartis Institute for Biomedical Research; Novartis Campus CH-4056 Basel, Switzerland
| | - Caroline Gubser Keller
- Developmental and Molecular Pathway, Computational Biology; Novartis Institute for Biomedical Research; Novartis Campus CH-4056 Basel, Switzerland
| |
Collapse
|
12
|
Dias Pires MJ, Poeira DL, Marques MMB. Metal-Catalyzed Cross-Coupling Reactions of Aminopyridines. European J Org Chem 2015. [DOI: 10.1002/ejoc.201500952] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
13
|
Latli B, Reeves JT, Tan Z, Hrapchak M, Song JJ, Busacca CB, Senanayake CH. Synthesis of two potent glucocorticoid receptor agonists labeled with carbon-14 and stable isotopes. J Labelled Comp Radiopharm 2015; 58:445-52. [PMID: 26391408 DOI: 10.1002/jlcr.3349] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2015] [Revised: 08/21/2015] [Accepted: 08/30/2015] [Indexed: 11/08/2022]
Abstract
Two potent glucocorticoid receptor agonists were prepared labeled with carbon-14 and with stable isotopes to perform drug metabolism, pharmacokinetics, and bioanalytical studies. Carbon-14 labeled (1) was obtained from an enantiopure alkyne (5) via a Sonogashira coupling to a previously reported 5-amino-4-iodo-[2-(14)C]pyrimidine [(14)C]-(6), followed by a base-mediated cyclization (1) in 72% overall radiochemical yield. Carbon-14 labeled (2) was prepared in five steps employing a key benzoic acid intermediate [(14)C]-(13), which was synthesized in one pot from enolization of trifluoromethylketone (12), followed by bromine-magnesium exchange and then electrophile trapping reaction with [(14)C]-carbon dioxide. A chiral auxiliary (S)-1-(4-methoxyphenyl)ethylamine was then coupled to this acid to give [(14)C]-(15). Propargylation and separation of diastereoisomers by crystallizations gave the desired diastereomer [(14)C]-(17) in 34% yield. Sonogashira coupling to iodopyridine (10) followed by cyclization to the azaindole [(14)C]-(18) and finally removal of the chiral auxiliary gave [(14)C]-(2) in 7% overall yield. For stable isotope syntheses, [(13)C6]-(1) was obtained in three steps using [(13)C4]-(6) and trimethylsilylacetylene-[(13)C2] in 26% yield, while [(2)H5]-(2) was obtained by first preparing the iodopyridine [(2)H5]-(10) in five steps. Then, Sonogashira coupling to chiral alkyne (24) and cyclization gave [(2)H5]-(2) in 42% overall yield.
Collapse
Affiliation(s)
- Bachir Latli
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, PO Box 368, Ridgefield, CT, USA
| | - Jonathan T Reeves
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, PO Box 368, Ridgefield, CT, USA
| | - Zhulin Tan
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, PO Box 368, Ridgefield, CT, USA
| | - Matt Hrapchak
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, PO Box 368, Ridgefield, CT, USA
| | - Jinhua J Song
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, PO Box 368, Ridgefield, CT, USA
| | - Carl B Busacca
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, PO Box 368, Ridgefield, CT, USA
| | - Chris H Senanayake
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, PO Box 368, Ridgefield, CT, USA
| |
Collapse
|
14
|
Yang MG, Dhar TGM, Xiao Z, Xiao HY, Duan JJW, Jiang B, Galella MA, Cunningham M, Wang J, Habte S, Shuster D, McIntyre KW, Carman J, Holloway DA, Somerville JE, Nadler SG, Salter-Cid L, Barrish JC, Weinstein DS. Improving the Pharmacokinetic and CYP Inhibition Profiles of Azaxanthene-Based Glucocorticoid Receptor Modulators—Identification of (S)-5-(2-(9-Fluoro-2-(4-(2-hydroxypropan-2-yl)phenyl)-5H-chromeno[2,3-b]pyridin-5-yl)-2-methylpropanamido)-N-(tetrahydro-2H-pyran-4-yl)-1,3,4-thiadiazole-2-carboxamide (BMS-341). J Med Chem 2015; 58:4278-90. [DOI: 10.1021/acs.jmedchem.5b00257] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- Michael G. Yang
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - T. G. Murali Dhar
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Zili Xiao
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Hai-Yun Xiao
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - James J.-W. Duan
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Bin Jiang
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Michael A. Galella
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Mark Cunningham
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Jinhong Wang
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Sium Habte
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - David Shuster
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Kim W. McIntyre
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Julie Carman
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Deborah A. Holloway
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - John E. Somerville
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Steven G. Nadler
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Luisa Salter-Cid
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Joel C. Barrish
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - David S. Weinstein
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| |
Collapse
|
15
|
Nechayev MA, Gorobets NY, Shishkina SV, Shishkin OV, Kovalenko SM. Microwave-assisted acid-catalyzed nucleophilic heteroaromatic substitution: the synthesis of 7-amino-6-azaindoles. Tetrahedron 2015. [DOI: 10.1016/j.tet.2014.12.057] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
16
|
Harcken C, Riether D, Liu P, Razavi H, Patel U, Lee T, Bosanac T, Ward Y, Ralph M, Chen Z, Souza D, Nelson RM, Kukulka A, Fadra-Khan TN, Zuvela-Jelaska L, Patel M, Thomson DS, Nabozny GH. Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate. ACS Med Chem Lett 2014; 5:1318-23. [PMID: 25516791 DOI: 10.1021/ml500387y] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2014] [Accepted: 11/17/2014] [Indexed: 01/15/2023] Open
Abstract
A series of nonsteroidal "dissociated" glucocorticoid receptor agonists was optimized for drug-like properties such as cytochrome P450 inhibition, metabolic stability, aqueous solubility, and hERG ion channel inhibition. This effort culminated in the identification of the clinical candidate compound ( R )-39.
Collapse
Affiliation(s)
- Christian Harcken
- Department of Medicinal
Chemistry
and Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Doris Riether
- Department of Medicinal
Chemistry
and Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Pingrong Liu
- Department of Medicinal
Chemistry
and Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Hossein Razavi
- Department of Medicinal
Chemistry
and Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Usha Patel
- Department of Medicinal
Chemistry
and Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Thomas Lee
- Department of Medicinal
Chemistry
and Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Todd Bosanac
- Department of Medicinal
Chemistry
and Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Yancey Ward
- Department of Medicinal
Chemistry
and Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Mark Ralph
- Department of Medicinal
Chemistry
and Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Zhidong Chen
- Department of Medicinal
Chemistry
and Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Donald Souza
- Department of Medicinal
Chemistry
and Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Richard M. Nelson
- Department of Medicinal
Chemistry
and Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Alison Kukulka
- Department of Medicinal
Chemistry
and Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Tazmeen N. Fadra-Khan
- Department of Medicinal
Chemistry
and Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Ljiljana Zuvela-Jelaska
- Department of Medicinal
Chemistry
and Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Mita Patel
- Department of Medicinal
Chemistry
and Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - David S. Thomson
- Department of Medicinal
Chemistry
and Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Gerald H. Nabozny
- Department of Medicinal
Chemistry
and Department of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| |
Collapse
|
17
|
Patel MR, Bhatt A, Steffen JD, Chergui A, Murai J, Pommier Y, Pascal JM, Trombetta LD, Fronczek FR, Talele TT. Discovery and structure-activity relationship of novel 2,3-dihydrobenzofuran-7-carboxamide and 2,3-dihydrobenzofuran-3(2H)-one-7-carboxamide derivatives as poly(ADP-ribose)polymerase-1 inhibitors. J Med Chem 2014; 57:5579-601. [PMID: 24922587 PMCID: PMC4094269 DOI: 10.1021/jm5002502] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
![]()
Novel
substituted 2,3-dihydrobenzofuran-7-carboxamide (DHBF-7-carboxamide)
and 2,3-dihydrobenzofuran-3(2H)-one-7-carboxamide
(DHBF-3-one-7-carboxamide) derivatives were synthesized and evaluated
as inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1). A structure-based
design strategy resulted in lead compound 3 (DHBF-7-carboxamide;
IC50 = 9.45 μM). To facilitate synthetically feasible
derivatives, an alternative core was designed, DHBF-3-one-7-carboxamide
(36, IC50 = 16.2 μM). The electrophilic
2-position of this scaffold was accessible for extended modifications.
Substituted benzylidene derivatives at the 2-position were found to
be the most potent, with 3′,4′-dihydroxybenzylidene 58 (IC50 = 0.531 μM) showing a 30-fold improvement
in potency. Various heterocycles attached at the 4′-hydroxyl/4′-amino
of the benzylidene moiety resulted in significant improvement in inhibition
of PARP-1 activity (e.g., compounds 66–68, 70, 72, and 73; IC50 values from 0.718 to 0.079 μM). Compound 66 showed
selective cytotoxicity in BRCA2-deficient DT40 cells.
Crystal structures of three inhibitors (compounds (−)-13c, 59, and 65) bound to
a multidomain PARP-1 structure were obtained, providing insights into
further development of these inhibitors.
Collapse
Affiliation(s)
- Maulik R Patel
- Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University , Queens, New York 11439, United States
| | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Hu Y, Li CY, Wang XM, Yang YH, Zhu HL. 1,3,4-Thiadiazole: synthesis, reactions, and applications in medicinal, agricultural, and materials chemistry. Chem Rev 2014; 114:5572-610. [PMID: 24716666 DOI: 10.1021/cr400131u] [Citation(s) in RCA: 322] [Impact Index Per Article: 32.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Affiliation(s)
- Yang Hu
- State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University , Nanjing 210093, People's Republic of China
| | | | | | | | | |
Collapse
|
19
|
Razavi H, Riether D, Harcken C, Bentzien J, Dinallo RM, Souza D, Nelson RM, Kukulka A, Fadra-Khan TN, Pack EJ, Zuvela-Jelaska L, Pelletier J, Panzenbeck M, Torcellini CA, Proudfoot JR, Nabozny GH, Thomson DS. Discovery of a potent and dissociated non-steroidal glucocorticoid receptor agonist containing an alkyl carbinol pharmacophore. Bioorg Med Chem Lett 2014; 24:1934-40. [DOI: 10.1016/j.bmcl.2014.03.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2013] [Revised: 02/27/2014] [Accepted: 03/03/2014] [Indexed: 10/25/2022]
|
20
|
Harcken C, Riether D, Kuzmich D, Liu P, Betageri R, Ralph M, Emmanuel M, Reeves JT, Berry A, Souza D, Nelson RM, Kukulka A, Fadra TN, Zuvela-Jelaska L, Dinallo R, Bentzien J, Nabozny GH, Thomson DS. Identification of Highly Efficacious Glucocorticoid Receptor Agonists with a Potential for Reduced Clinical Bone Side Effects. J Med Chem 2014; 57:1583-98. [DOI: 10.1021/jm4019178] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Christian Harcken
- Department of Medicinal Chemistry,
Department of Immunology and Inflammation, Department of Chemical
Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Doris Riether
- Department of Medicinal Chemistry,
Department of Immunology and Inflammation, Department of Chemical
Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Daniel Kuzmich
- Department of Medicinal Chemistry,
Department of Immunology and Inflammation, Department of Chemical
Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Pingrong Liu
- Department of Medicinal Chemistry,
Department of Immunology and Inflammation, Department of Chemical
Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Raj Betageri
- Department of Medicinal Chemistry,
Department of Immunology and Inflammation, Department of Chemical
Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Mark Ralph
- Department of Medicinal Chemistry,
Department of Immunology and Inflammation, Department of Chemical
Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Michel Emmanuel
- Department of Medicinal Chemistry,
Department of Immunology and Inflammation, Department of Chemical
Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Jonathan T. Reeves
- Department of Medicinal Chemistry,
Department of Immunology and Inflammation, Department of Chemical
Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Angela Berry
- Department of Medicinal Chemistry,
Department of Immunology and Inflammation, Department of Chemical
Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Donald Souza
- Department of Medicinal Chemistry,
Department of Immunology and Inflammation, Department of Chemical
Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Richard M. Nelson
- Department of Medicinal Chemistry,
Department of Immunology and Inflammation, Department of Chemical
Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Alison Kukulka
- Department of Medicinal Chemistry,
Department of Immunology and Inflammation, Department of Chemical
Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Tazmeen N. Fadra
- Department of Medicinal Chemistry,
Department of Immunology and Inflammation, Department of Chemical
Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Ljiljana Zuvela-Jelaska
- Department of Medicinal Chemistry,
Department of Immunology and Inflammation, Department of Chemical
Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Roger Dinallo
- Department of Medicinal Chemistry,
Department of Immunology and Inflammation, Department of Chemical
Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Jörg Bentzien
- Department of Medicinal Chemistry,
Department of Immunology and Inflammation, Department of Chemical
Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Gerald H. Nabozny
- Department of Medicinal Chemistry,
Department of Immunology and Inflammation, Department of Chemical
Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - David S. Thomson
- Department of Medicinal Chemistry,
Department of Immunology and Inflammation, Department of Chemical
Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| |
Collapse
|
21
|
Chikkade PK, Shimizu Y, Kanai M. Catalytic enantioselective synthesis of 2-(2-hydroxyethyl)indole scaffolds via consecutive intramolecular amido-cupration of allenes and asymmetric addition of carbonyl compounds. Chem Sci 2014. [DOI: 10.1039/c3sc52803k] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
22
|
Xiao HY, Wu DR, Sheppeck JE, Habte SF, Cunningham MD, Somerville JE, Barrish JC, Nadler SG, Dhar TM. Heterocyclic glucocorticoid receptor modulators with a 2,2-dimethyl-3-phenyl-N-(thiazol or thiadiazol-2-yl)propanamide core. Bioorg Med Chem Lett 2013; 23:5571-4. [DOI: 10.1016/j.bmcl.2013.08.049] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2013] [Accepted: 08/09/2013] [Indexed: 01/07/2023]
|
23
|
|
24
|
Reeves JT, Fandrick DR, Tan Z, Song JJ, Rodriguez S, Qu B, Kim S, Niemeier O, Li Z, Byrne D, Campbell S, Chitroda A, DeCroos P, Fachinger T, Fuchs V, Gonnella NC, Grinberg N, Haddad N, Jäger B, Lee H, Lorenz JC, Ma S, Narayanan BA, Nummy LJ, Premasiri A, Roschangar F, Sarvestani M, Shen S, Spinelli E, Sun X, Varsolona RJ, Yee N, Brenner M, Senanayake CH. Development of a Large Scale Asymmetric Synthesis of the Glucocorticoid Agonist BI 653048 BS H3PO4. J Org Chem 2013; 78:3616-35. [DOI: 10.1021/jo400079z] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Jonathan T. Reeves
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Daniel R. Fandrick
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Zhulin Tan
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Jinhua J. Song
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Sonia Rodriguez
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Bo Qu
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Soojin Kim
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Oliver Niemeier
- Boehringer Ingelheim GmbH & Co. KG, Binger Strasse 173, 55216 Ingelheim am Rhein, Germany
| | - Zhibin Li
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Denis Byrne
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Scot Campbell
- Analytical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O.
Box 368, Ridgefield, Connecticut, 06877-0368, United States
| | - Ashish Chitroda
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Phil DeCroos
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Thomas Fachinger
- Boehringer Ingelheim GmbH & Co. KG, Binger Strasse 173, 55216 Ingelheim am Rhein, Germany
| | - Victor Fuchs
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Nina C. Gonnella
- Analytical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O.
Box 368, Ridgefield, Connecticut, 06877-0368, United States
| | - Nelu Grinberg
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Nizar Haddad
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Burkhard Jäger
- Boehringer Ingelheim GmbH & Co. KG, Binger Strasse 173, 55216 Ingelheim am Rhein, Germany
| | - Heewon Lee
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Jon C. Lorenz
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Shengli Ma
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Bikshandarkoil A. Narayanan
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Larry J. Nummy
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Ajith Premasiri
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Frank Roschangar
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Max Sarvestani
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Sherry Shen
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Earl Spinelli
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Xiufeng Sun
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Richard J. Varsolona
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Nathan Yee
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| | - Michael Brenner
- Boehringer Ingelheim GmbH & Co. KG, Binger Strasse 173, 55216 Ingelheim am Rhein, Germany
| | - Chris H. Senanayake
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Old Ridgebury Road, P.O. Box 368, Ridgefield,
Connecticut, 06877-0368, United States
| |
Collapse
|
25
|
Hoashi Y, Takai T, Kotani E, Koike T. Synthesis of pyrazolo[1,5-a]pyridines by thermal intramolecular cyclization. Tetrahedron Lett 2013. [DOI: 10.1016/j.tetlet.2013.02.078] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
26
|
Fandrick DR, Reeves JT, Bakonyi JM, Nyalapatla PR, Tan Z, Niemeier O, Akalay D, Fandrick KR, Wohlleben W, Ollenberger S, Song JJ, Sun X, Qu B, Haddad N, Sanyal S, Shen S, Ma S, Byrne D, Chitroda A, Fuchs V, Narayanan BA, Grinberg N, Lee H, Yee N, Brenner M, Senanayake CH. Zinc Catalyzed and Mediated Asymmetric Propargylation of Trifluoromethyl Ketones with a Propargyl Boronate. J Org Chem 2013; 78:3592-615. [DOI: 10.1021/jo400080y] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- Daniel R. Fandrick
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Jonathan T. Reeves
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Johanna M. Bakonyi
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Prasanth R. Nyalapatla
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Zhulin Tan
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Oliver Niemeier
- Boehringer Ingelheim GmbH & Co KG, Binger Strasse 173, 55216 Ingelheim am Rhein, Germany
| | - Deniz Akalay
- Boehringer Ingelheim GmbH & Co KG, Binger Strasse 173, 55216 Ingelheim am Rhein, Germany
| | - Keith R. Fandrick
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Wolfgang Wohlleben
- Boehringer Ingelheim GmbH & Co KG, Binger Strasse 173, 55216 Ingelheim am Rhein, Germany
| | - Swetlana Ollenberger
- Boehringer Ingelheim GmbH & Co KG, Binger Strasse 173, 55216 Ingelheim am Rhein, Germany
| | - Jinhua J. Song
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Xiufeng Sun
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Bo Qu
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Nizar Haddad
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Sanjit Sanyal
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Sherry Shen
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Shengli Ma
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Denis Byrne
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Ashish Chitroda
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Victor Fuchs
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Bikshandarkoil A. Narayanan
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Nelu Grinberg
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Heewon Lee
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Nathan Yee
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| | - Michael Brenner
- Boehringer Ingelheim GmbH & Co KG, Binger Strasse 173, 55216 Ingelheim am Rhein, Germany
| | - Chris H. Senanayake
- Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury
Rd./PO BOX 368, Ridgefield, Connecticut 06877-0368, United States
| |
Collapse
|
27
|
van Lierop MJC, Alkema W, Laskewitz AJ, Dijkema R, van der Maaden HM, Smit MJ, Plate R, Conti PGM, Jans CGJM, Timmers CM, van Boeckel CAA, Lusher SJ, McGuire R, van Schaik RC, de Vlieg J, Smeets RL, Hofstra CL, Boots AMH, van Duin M, Ingelse BA, Schoonen WGEJ, Grefhorst A, van Dijk TH, Kuipers F, Dokter WHA. Org 214007-0: a novel non-steroidal selective glucocorticoid receptor modulator with full anti-inflammatory properties and improved therapeutic index. PLoS One 2012; 7:e48385. [PMID: 23152771 PMCID: PMC3495945 DOI: 10.1371/journal.pone.0048385] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2012] [Accepted: 09/24/2012] [Indexed: 11/18/2022] Open
Abstract
Glucocorticoids (GCs) such as prednisolone are potent immunosuppressive drugs but suffer from severe adverse effects, including the induction of insulin resistance. Therefore, development of so-called Selective Glucocorticoid Receptor Modulators (SGRM) is highly desirable. Here we describe a non-steroidal Glucocorticoid Receptor (GR)-selective compound (Org 214007-0) with a binding affinity to GR similar to that of prednisolone. Structural modelling of the GR-Org 214007-0 binding site shows disturbance of the loop between helix 11 and helix 12 of GR, confirmed by partial recruitment of the TIF2-3 peptide. Using various cell lines and primary human cells, we show here that Org 214007-0 acts as a partial GC agonist, since it repressed inflammatory genes and was less effective in induction of metabolic genes. More importantly, in vivo studies in mice indicated that Org 214007-0 retained full efficacy in acute inflammation models as well as in a chronic collagen-induced arthritis (CIA) model. Gene expression profiling of muscle tissue derived from arthritic mice showed a partial activity of Org 214007-0 at an equi-efficacious dosage of prednisolone, with an increased ratio in repression versus induction of genes. Finally, in mice Org 214007-0 did not induce elevated fasting glucose nor the shift in glucose/glycogen balance in the liver seen with an equi-efficacious dose of prednisolone. All together, our data demonstrate that Org 214007-0 is a novel SGRMs with an improved therapeutic index compared to prednisolone. This class of SGRMs can contribute to effective anti-inflammatory therapy with a lower risk for metabolic side effects.
Collapse
|
28
|
RAZAVI HOSSEIN, HARCKEN CHRISTIAN. Non-steroidal Dissociated Glucocorticoid Receptor Agonists. ANTI-INFLAMMATORY DRUG DISCOVERY 2012. [DOI: 10.1039/9781849735346-00481] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Synthetic glucocorticoids, such as dexamethasone and prednisolone, are amongst the most commonly used drugs due to their potent and efficacious anti-inflammatory and immunosuppressive properties. However, their long-term and/or high-dose administration is limited by a number of deleterious side-effects, including glucocorticoid-induced diabetes and osteoporosis. Glucocorticoids exert their effects through binding to the glucocorticoid receptor. Since the discovery of multiple differentiated down-stream functions of the glucocorticoid-bound receptor, such as gene transrepression and transactivation, researchers in academia and industry have been on a quest to discover novel glucocorticoids that achieve functional selectivity, hence dissociating the desired anti-inflammatory from the undesired side-effects. This review describes the current state of discovery and development of non-steroidal glucocorticoid receptor agonists. Several small-molecule drug candidates have advanced into clinical trials, and have shown promising early biomarker data, as well as beneficial effects in topical applications. However, a clinically efficacious and systemically available glucocorticoid with significantly reduced side-effects as compared to current steroidal drugs, the “Holy Grail” in immunology, is still elusive.
Collapse
Affiliation(s)
- HOSSEIN RAZAVI
- Department of Medicinal Chemistry Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, CT 06877 USA
| | - CHRISTIAN HARCKEN
- Department of Research Networking & Strategic Planning Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, CT 06877 USA
| |
Collapse
|
29
|
Z. Zard S, Bacqué E, El Qacémi M. A Flexible Convergent Route to Azaoxindoles, Azaindolines, Azaindoles, and Tetrahydroazaquinolones. HETEROCYCLES 2012. [DOI: 10.3987/com-11-s(p)24] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
30
|
Discovery of selective glucocorticoid receptor modulator MK-5932. Bioorg Med Chem 2011; 19:7374-86. [DOI: 10.1016/j.bmc.2011.10.054] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2011] [Revised: 10/10/2011] [Accepted: 10/18/2011] [Indexed: 11/22/2022]
|
31
|
Weinstein DS, Gong H, Doweyko AM, Cunningham M, Habte S, Wang JH, Holloway DA, Burke C, Gao L, Guarino V, Carman J, Somerville JE, Shuster D, Salter-Cid L, Dodd JH, Nadler SG, Barrish JC. Azaxanthene Based Selective Glucocorticoid Receptor Modulators: Design, Synthesis, and Pharmacological Evaluation of (S)-4-(5-(1-((1,3,4-Thiadiazol-2-yl)amino)-2-methyl-1-oxopropan-2-yl)-5H-chromeno[2,3-b]pyridin-2-yl)-2-fluoro-N,N-dimethylbenzamide (BMS-776532) and Its Methylene Homologue (BMS-791826). J Med Chem 2011; 54:7318-33. [DOI: 10.1021/jm200879j] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Affiliation(s)
- David S. Weinstein
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Hua Gong
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Arthur M. Doweyko
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Mark Cunningham
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Sium Habte
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Jin Hong Wang
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Deborah A. Holloway
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Christine Burke
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Ling Gao
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Victor Guarino
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Julie Carman
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - John E. Somerville
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - David Shuster
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Luisa Salter-Cid
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - John H. Dodd
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Steven G. Nadler
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Joel C. Barrish
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| |
Collapse
|
32
|
Betageri R, Gilmore T, Kuzmich D, Kirrane TM, Bentzien J, Wiedenmayer D, Bekkali Y, Regan J, Berry A, Latli B, Kukulka AJ, Fadra TN, Nelson RM, Goldrick S, Zuvela-Jelaska L, Souza D, Pelletier J, Dinallo R, Panzenbeck M, Torcellini C, Lee H, Pack E, Harcken C, Nabozny G, Thomson DS. Non-steroidal dissociated glucocorticoid agonists: indoles as A-ring mimetics and function-regulating pharmacophores. Bioorg Med Chem Lett 2011; 21:6842-51. [PMID: 21963986 DOI: 10.1016/j.bmcl.2011.09.018] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2011] [Revised: 09/01/2011] [Accepted: 09/06/2011] [Indexed: 11/30/2022]
Abstract
We report a SAR of non-steroidal glucocorticoid mimetics that utilize indoles as A-ring mimetics. Detailed SAR is discussed with a focus on improving PR and MR selectivity, GR agonism, and in vitro dissociation profile. SAR analysis led to compound (R)-33 which showed high PR and MR selectivity, potent agonist activity, and reduced transactivation activity in the MMTV and aromatase assays. The compound is equipotent to prednisolone in the LPS-TNF model of inflammation. In mouse CIA, at 30 mg/kg compound (R)-33 inhibited disease progression with an efficacy similar to the 3 mg/kg dose of prednisolone.
Collapse
Affiliation(s)
- Raj Betageri
- Department of Medicinal Chemistry, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, CT 06877, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Norman P. Boehringer Ingleheim's selective glucocorticoid receptor agonist development candidate: evaluation of WO2010141331, WO2010141332 and WO2010141333. Expert Opin Ther Pat 2011; 21:1137-42. [DOI: 10.1517/13543776.2011.581229] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
34
|
Sumiyoshi T, Tojo K, Urabe D, Tobe M. Asymmetric synthesis of the 6-cyanoindole derivatives as non-steroidal glucocorticoid receptor modulators using (+)- and (−)-tert-butyl 6-cyano-3-[3-ethoxy-1,1,1-trifluoro-2-hydroxy-3-oxopropan-2-yl]-1H-indole-1-carboxylate. ACTA ACUST UNITED AC 2011. [DOI: 10.1016/j.tetasy.2011.01.020] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
35
|
Yang BV, Weinstein DS, Doweyko LM, Gong H, Vaccaro W, Huynh T, Xiao HY, Doweyko AM, McKay L, Holloway DA, Somerville JE, Habte S, Cunningham M, McMahon M, Townsend R, Shuster D, Dodd JH, Nadler SG, Barrish JC. Dimethyl-diphenyl-propanamide derivatives as nonsteroidal dissociated glucocorticoid receptor agonists. J Med Chem 2010; 53:8241-51. [PMID: 21073190 DOI: 10.1021/jm100957a] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
A series of 2,2-dimethyl-3,3-diphenyl-propanamides as novel glucocorticoid receptor modulators is reported. SAR exploration led to the identification of 4-hydroxyphenyl propanamide derivatives displaying good agonist activity in GR-mediated transrepression assays and reduced agonist activity in GR-mediated transactivation assays. Compounds 17 and 30 showed anti-inflammatory activity comparable to prednisolone in the rat carrageenan-induced paw edema model, with markedly decreased side effects with regard to increases in blood glucose and expression of hepatic tyrosine aminotransferase. A hypothetical binding mode accounting for the induction of the functional activity by a 4-hydroxyl group is proposed.
Collapse
Affiliation(s)
- Bingwei V Yang
- Bristol-Myers Squibb Company, Research and Development, Princeton, New Jersey 08543-4000, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|